<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3551">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 19, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01864603</url>
  </required_header>
  <id_info>
    <org_study_id>SEARCH</org_study_id>
    <nct_id>NCT01864603</nct_id>
  </id_info>
  <brief_title>Sustainable East Africa Research in Community Health</brief_title>
  <acronym>SEARCH</acronym>
  <official_title>Sustainable East Africa Research in Community Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Infectious Diseases Research Collaboration, Uganda</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Makerere University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kenya Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>World Bank</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>United States President's Emergency Plan for AIDS Relief</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The SEARCH study aims to test evidenced-based innovative community based interventions that&#xD;
      lead to the elimination of HIV in rural communities in East Africa using a multi-disease&#xD;
      approach. The first phase of the study will quantify the impact of early HIV diagnosis using&#xD;
      a streamlined and immediate ART (antiretroviral therapy). The second phase of the study, will&#xD;
      quantify the impact of targeted Pre-Exposure Prophylaxis (PrEP) in the context of universal&#xD;
      treatment and streamlined care. The study intervention is designed to improve the entire&#xD;
      continuum of care, to reduce structural barriers for all populations including those most &quot;at&#xD;
      risk&quot;.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The SEARCH study aims to test evidenced-based innovative community based interventions that&#xD;
      lead to the elimination of HIV in rural communities in East Africa using a multi-disease&#xD;
      approach. The first phase of the study will quantify the impact of early HIV diagnosis using&#xD;
      a streamlined and immediate ART (antiretroviral therapy). The second phase of the study, will&#xD;
      quantify the impact of targeted Pre-Exposure Prophylaxis (PrEP) in the context of universal&#xD;
      treatment and streamlined care. The study intervention is designed to improve the entire&#xD;
      continuum of care, to reduce structural barriers for all populations including those most &quot;at&#xD;
      risk&quot;.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">April 2021</completion_date>
  <primary_completion_date type="Actual">April 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative HIV Incidence</measure>
    <time_frame>3 years follow up</time_frame>
    <description>Cumulative 3 year HIV incidence in men and women ages ≥15 years after the start of Phase I intervention.&#xD;
Mean was calculated as the average across clusters of the cluster-level cumulative incidence.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HIV Incidence</measure>
    <time_frame>3 years follow up</time_frame>
    <description>HIV incidence rate in men and women ages ≥15 years after the start of Phase II intervention (started after 3 years of Phase I).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incident TB Associated With HIV</measure>
    <time_frame>3 years follow up</time_frame>
    <description>Cumulative incidence of TB or death due to illness among HIV+ population. Mean was calculated as the average across clusters of the cluster-level cumulative incidence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Mortality</measure>
    <time_frame>3 years follow up</time_frame>
    <description>Mortality risk among HIV+ population. Mean was calculated as the average across clusters of the cluster-level cumulative incidence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-free Infant Survival</measure>
    <time_frame>3 years follow up</time_frame>
    <description>Probability of an infant born to an HIV+ mother remaining alive and HIV uninfected.&#xD;
Mean was calculated as the average across clusters of the cluster-level cumulative incidence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of HIV+ Adults With HIV RNA &lt;=500 c/mL</measure>
    <time_frame>3 years follow up</time_frame>
    <description>Percent of HIV+ adults with HIV RNA &lt;=500 c/mL. Mean was calculated as the average across clusters of the cluster-level cumulative incidence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time in Care for HIV+ Adults With Baseline Viremia</measure>
    <time_frame>3 years follow up</time_frame>
    <description>Percent of time spent actively engaged in HIV care among HIV+ adults with baseline viremia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Incidence of ART-initiation</measure>
    <time_frame>3 years follow up</time_frame>
    <description>Proportion of baseline HIV+ ART-naive persons who initiate ART Mean was calculated as the average across clusters of the cluster-level cumulative incidence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypertension Control</measure>
    <time_frame>3 years follow up</time_frame>
    <description>hypertension control (greater than or equal to 140 mg Hg systolic or 90 mg Hg diastolic after 3 repeated readings) at year 3 among adults aged &gt;= 30 years with hypertension.&#xD;
Mean was calculated as the average across clusters of the cluster-level cumulative incidence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to PrEP Treatment</measure>
    <time_frame>3 years follow up</time_frame>
    <description>Number of patients with adherence to PrEP treatment (self reported adherence at &gt;=1 visit)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Adults' on- and Off-farm Employment</measure>
    <time_frame>3 years follow up</time_frame>
    <description>HIV+ adults with on- and off-farm employment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Year 3 Viremia Among ART-experienced Persons With Baseline Viremia</measure>
    <time_frame>3 years follow up</time_frame>
    <description>Plasma HIV RNA &lt;400 cps/ml Mean was calculated as the average across clusters of the cluster-level cumulative incidence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Linkage to Care</measure>
    <time_frame>30 days after HIV test</time_frame>
    <description>Proportion of Persons Attending an HIV Clinic Visit by 30 Days After HIV Test Mean was calculated as the average across clusters of the cluster-level cumulative incidence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV Incidence Rate</measure>
    <time_frame>3 years follow up</time_frame>
    <description>HIV incidence rates during the first and third year of follow up; Results from the Control arm are not provided because annual HIV incidence was not measured in the control arm (annual HIV testing was only conducted in the intervention arm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Transmitted HIV Drug-resistance Mutations</measure>
    <time_frame>Baseline</time_frame>
    <description>HIV NNRTI drug-resistance mutations found at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Chronic Kidney Disease (CKD)</measure>
    <time_frame>3 years follow up</time_frame>
    <description>Percentage of participants with chronic kidney disease (CKD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Costs of Programming (ART)</measure>
    <time_frame>Follow up year 3</time_frame>
    <description>Cost of ART streamlined care delivery amount HIV+ persons</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150395</enrollment>
  <condition>HIV</condition>
  <condition>Tuberculosis</condition>
  <condition>Hypertension</condition>
  <condition>Diabetes</condition>
  <condition>Maternal Child Health</condition>
  <condition>Cost Effectiveness</condition>
  <arm_group>
    <arm_group_label>1st: universal test and treat; 2nd: targeted PrEP and cascade</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention arm first phase: annual universal community-based HIV and multi-disease testing; ART for all HIV+ using streamlined care delivery&#xD;
Intervention arm second phase: baseline universal community-based HIV and multi-disease testing; ART for all HIV+ using streamlined care delivery + targeted PrEP, and targeted HIV testing interventions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1st: baseline community testing; 2nd: None</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Comparator arm first phase: baseline community-based HIV and multi-disease testing; ART by country standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Universal ART in a streamlined care model</intervention_name>
    <description>immediate ART start for all HIV+ in community with streamlined care</description>
    <arm_group_label>1st: baseline community testing; 2nd: None</arm_group_label>
    <arm_group_label>1st: universal test and treat; 2nd: targeted PrEP and cascade</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Annual Community Health Campaigns</intervention_name>
    <description>HIV and multi-disease testing for all community members</description>
    <arm_group_label>1st: universal test and treat; 2nd: targeted PrEP and cascade</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Targeted PrEP and Targeted testing interventions</intervention_name>
    <arm_group_label>1st: universal test and treat; 2nd: targeted PrEP and cascade</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Baseline community-based HIV and multi-disease testing</intervention_name>
    <description>HIV and multi-disease testing for all community members at baseline only</description>
    <arm_group_label>1st: baseline community testing; 2nd: None</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Community Level Inclusion Criteria:&#xD;
&#xD;
          -  Non-adjacent geopolitical units in south-western and eastern Uganda and western Kenya.&#xD;
&#xD;
          -  Most recent census population between 9,000 and 11,000 individuals.&#xD;
&#xD;
          -  Served by an ART providing health center.&#xD;
&#xD;
          -  Community leader commitment for study participation and implementation.&#xD;
&#xD;
          -  Accessibility to health center via a maintained transportation route.&#xD;
&#xD;
          -  Community location with sufficient distance from other potential study communities to&#xD;
             limit contamination of intervention or control conditions (buffer zone)&#xD;
&#xD;
        Individual Level Inclusion Criteria:&#xD;
&#xD;
          -  Residency of individual in community, defined as present in household for at least 6&#xD;
             months of the calendar year.&#xD;
&#xD;
        Community Level Exclusion Criteria:&#xD;
&#xD;
          -  Presence of ongoing community-based ART intervention strategies that provide treatment&#xD;
             outside of the current in-country treatment guidelines.&#xD;
&#xD;
          -  An urban setting defined as a city with a population of 100,000 or more inhabitants.&#xD;
&#xD;
          -  Absence of a health center able to provide ART.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diane Havlir, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Moses Kamya, MBChB, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Makerere University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maya Petersen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Berkeley</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nyanza Province Kenya</name>
      <address>
        <city>Nyanza Province</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Uganda</name>
      <address>
        <city>Mbale/Tororo Region</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwestern Uganda</name>
      <address>
        <city>Mbarara Region</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kenya</country>
    <country>Uganda</country>
  </location_countries>
  <link>
    <url>http://www.searchendaids.com</url>
    <description>SEARCH Collaboration website</description>
  </link>
  <reference>
    <citation>Balzer LB, Petersen ML, van der Laan MJ; SEARCH Consortium. Adaptive pair-matching in randomized trials with unbiased and efficient effect estimation. Stat Med. 2015 Mar 15;34(6):999-1011. doi: 10.1002/sim.6380. Epub 2014 Nov 25.</citation>
    <PMID>25421503</PMID>
  </reference>
  <reference>
    <citation>Camlin CS, Seeley J, Viljoen L, Vernooij E, Simwinga M, Reynolds L, Reis R, Plank R, Orne-Gliemann J, McGrath N, Larmarange J, Hoddinott G, Getahun M, Charlebois ED, Bond V. Strengthening universal HIV 'test-and-treat' approaches with social science research. AIDS. 2016 Mar 27;30(6):969-70. doi: 10.1097/QAD.0000000000001008.</citation>
    <PMID>26959355</PMID>
  </reference>
  <reference>
    <citation>SEARCH Collaboration. Evaluating the feasibility and uptake of a community-led HIV testing and multi-disease health campaign in rural Uganda. J Int AIDS Soc. 2017 Mar 30;20(1):21514. doi: 10.7448/IAS.20.1.21514.</citation>
    <PMID>28406269</PMID>
  </reference>
  <reference>
    <citation>Balzer LB, van der Laan MJ, Petersen ML; SEARCH Collaboration. Adaptive pre-specification in randomized trials with and without pair-matching. Stat Med. 2016 Nov 10;35(25):4528-4545. doi: 10.1002/sim.7023. Epub 2016 Jul 19.</citation>
    <PMID>27436797</PMID>
  </reference>
  <reference>
    <citation>Balzer L, Staples P, Onnela JP, DeGruttola V. Using a network-based approach and targeted maximum likelihood estimation to evaluate the effect of adding pre-exposure prophylaxis to an ongoing test-and-treat trial. Clin Trials. 2017 Apr;14(2):201-210. doi: 10.1177/1740774516679666. Epub 2017 Jan 26.</citation>
    <PMID>28124579</PMID>
  </reference>
  <reference>
    <citation>Tram KH, Mwangwa F, Atukunda M, Owaraganise A, Ayieko J, Plenty A, Kwariisima D, Clark TD, Petersen ML, Charlebois ED, Kamya MR, Chamie G, Havlir DV, Marquez C; SEARCH Collaboration. Isoniazid Preventive Therapy Completion in the Era of Differentiated HIV Care. J Acquir Immune Defic Syndr. 2017 Dec 15;76(5):e115-e117. doi: 10.1097/QAI.0000000000001540.</citation>
    <PMID>28885271</PMID>
  </reference>
  <reference>
    <citation>Puryear SB, Balzer LB, Ayieko J, Kwarisiima D, Hahn JA, Charlebois ED, Clark TD, Cohen CR, Bukusi EA, Kamya MR, Petersen ML, Havlir DV, Chamie G. Associations between alcohol use and HIV care cascade outcomes among adults undergoing population-based HIV testing in East Africa. AIDS. 2020 Mar 1;34(3):405-413. doi: 10.1097/QAD.0000000000002427.</citation>
    <PMID>31725431</PMID>
  </reference>
  <reference>
    <citation>Balzer LB, Havlir DV, Kamya MR, Chamie G, Charlebois ED, Clark TD, Koss CA, Kwarisiima D, Ayieko J, Sang N, Kabami J, Atukunda M, Jain V, Camlin CS, Cohen CR, Bukusi EA, Van Der Laan M, Petersen ML. Machine Learning to Identify Persons at High-Risk of Human Immunodeficiency Virus Acquisition in Rural Kenya and Uganda. Clin Infect Dis. 2020 Dec 3;71(9):2326-2333. doi: 10.1093/cid/ciz1096.</citation>
    <PMID>31697383</PMID>
  </reference>
  <reference>
    <citation>Marcus JL, Sewell WC, Balzer LB, Krakower DS. Artificial Intelligence and Machine Learning for HIV Prevention: Emerging Approaches to Ending the Epidemic. Curr HIV/AIDS Rep. 2020 Jun;17(3):171-179. doi: 10.1007/s11904-020-00490-6. Review.</citation>
    <PMID>32347446</PMID>
  </reference>
  <reference>
    <citation>Balzer LB, Ayieko J, Kwarisiima D, Chamie G, Charlebois ED, Schwab J, van der Laan MJ, Kamya MR, Havlir DV, Petersen ML. Far from MCAR: Obtaining Population-level Estimates of HIV Viral Suppression. Epidemiology. 2020 Sep;31(5):620-627. doi: 10.1097/EDE.0000000000001215. Erratum in: Epidemiology. 2021 Sep 1;32(5):e25.</citation>
    <PMID>32452912</PMID>
  </reference>
  <reference>
    <citation>Jewell BL, Balzer LB, Clark TD, Charlebois ED, Kwarisiima D, Kamya MR, Havlir DV, Petersen ML, Bershteyn A. Predicting HIV Incidence in the SEARCH Trial: A Mathematical Modeling Study. J Acquir Immune Defic Syndr. 2021 Aug 1;87(4):1024-1031. doi: 10.1097/QAI.0000000000002684.</citation>
    <PMID>33770065</PMID>
  </reference>
  <results_reference>
    <citation>Chamie G, Kwarisiima D, Clark TD, Kabami J, Jain V, Geng E, Petersen ML, Thirumurthy H, Kamya MR, Havlir DV, Charlebois ED; SEARCH Collaboration. Leveraging rapid community-based HIV testing campaigns for non-communicable diseases in rural Uganda. PLoS One. 2012;7(8):e43400. Epub 2012 Aug 20.</citation>
    <PMID>22916256</PMID>
  </results_reference>
  <results_reference>
    <citation>Thirumurthy H, Chamie G, Jain V, Kabami J, Kwarisiima D, Clark TD, Geng E, Petersen ML, Charlebois ED, Kamya MR, Havlir DV; SEARCH Collaboration. Improved employment and education outcomes in households of HIV-infected adults with high CD4 cell counts: evidence from a community health campaign in Uganda. AIDS. 2013 Feb 20;27(4):627-34. doi: 10.1097/QAD.0b013e32835c54d8.</citation>
    <PMID>23169332</PMID>
  </results_reference>
  <results_reference>
    <citation>Jain V, Liegler T, Kabami J, Chamie G, Clark TD, Black D, Geng EH, Kwarisiima D, Wong JK, Abdel-Mohsen M, Sonawane N, Aweeka FT, Thirumurthy H, Petersen ML, Charlebois ED, Kamya MR, Havlir DV; SEARCH Collaboration. Assessment of population-based HIV RNA levels in a rural east African setting using a fingerprick-based blood collection method. Clin Infect Dis. 2013 Feb;56(4):598-605. doi: 10.1093/cid/cis881. Epub 2012 Dec 12. Erratum in: Clin Infect Dis. 2014 Aug 1;59(3):463.</citation>
    <PMID>23243180</PMID>
  </results_reference>
  <results_reference>
    <citation>Namusobya J, Semitala FC, Amanyire G, Kabami J, Chamie G, Bogere J, Jain V, Clark TD, Charlebois E, Havlir DV, Kamya M, Geng EH. High retention in care among HIV-infected patients entering care with CD4 levels &gt;350 cells/μL under routine program conditions in Uganda. Clin Infect Dis. 2013 Nov;57(9):1343-50. doi: 10.1093/cid/cit490. Epub 2013 Jul 29.</citation>
    <PMID>23899683</PMID>
  </results_reference>
  <results_reference>
    <citation>Jain V, Byonanebye DM, Liegler T, Kwarisiima D, Chamie G, Kabami J, Petersen ML, Balzer LB, Clark TD, Black D, Thirumurthy H, Geng EH, Charlebois ED, Amanyire G, Kamya MR, Havlir DV; SEARCH Collaboration. Changes in population HIV RNA levels in Mbarara, Uganda, during scale-up of HIV antiretroviral therapy access. J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):327-32. doi: 10.1097/QAI.0000000000000021.</citation>
    <PMID>24146022</PMID>
  </results_reference>
  <results_reference>
    <citation>Chamie G, Kwarisiima D, Clark TD, Kabami J, Jain V, Geng E, Balzer LB, Petersen ML, Thirumurthy H, Charlebois ED, Kamya MR, Havlir DV. Uptake of community-based HIV testing during a multi-disease health campaign in rural Uganda. PLoS One. 2014 Jan 2;9(1):e84317. doi: 10.1371/journal.pone.0084317. eCollection 2014.</citation>
    <PMID>24392124</PMID>
  </results_reference>
  <results_reference>
    <citation>Kotwani P, Kwarisiima D, Clark TD, Kabami J, Geng EH, Jain V, Chamie G, Petersen ML, Thirumurthy H, Kamya MR, Charlebois ED, Havlir DV; SEARCH Collaboration. Epidemiology and awareness of hypertension in a rural Ugandan community: a cross-sectional study. BMC Public Health. 2013 Dec 9;13:1151. doi: 10.1186/1471-2458-13-1151.</citation>
    <PMID>24321133</PMID>
  </results_reference>
  <results_reference>
    <citation>Kotwani P, Balzer L, Kwarisiima D, Clark TD, Kabami J, Byonanebye D, Bainomujuni B, Black D, Chamie G, Jain V, Thirumurthy H, Kamya MR, Geng EH, Petersen ML, Havlir DV, Charlebois ED; SEARCH Collaboration. Evaluating linkage to care for hypertension after community-based screening in rural Uganda. Trop Med Int Health. 2014 Apr;19(4):459-68. doi: 10.1111/tmi.12273. Epub 2014 Feb 3.</citation>
    <PMID>24495307</PMID>
  </results_reference>
  <results_reference>
    <citation>Jain V, Byonanebye DM, Amanyire G, Kwarisiima D, Black D, Kabami J, Chamie G, Clark TD, Rooney JF, Charlebois ED, Kamya MR, Havlir DV; SEARCH Collaboration. Successful antiretroviral therapy delivery and retention in care among asymptomatic individuals with high CD4+ T-cell counts above 350 cells/μl in rural Uganda. AIDS. 2014 Sep 24;28(15):2241-9. doi: 10.1097/QAD.0000000000000401.</citation>
    <PMID>25022596</PMID>
  </results_reference>
  <results_reference>
    <citation>Kwarisiima D, Balzer L, Heller D, Kotwani P, Chamie G, Clark T, Ayieko J, Mwangwa F, Jain V, Byonanebye D, Petersen M, Havlir D, Kamya MR. Population-Based Assessment of Hypertension Epidemiology and Risk Factors among HIV-Positive and General Populations in Rural Uganda. PLoS One. 2016 May 27;11(5):e0156309. doi: 10.1371/journal.pone.0156309. eCollection 2016.</citation>
    <PMID>27232186</PMID>
  </results_reference>
  <results_reference>
    <citation>Chamie G, Clark TD, Kabami J, Kadede K, Ssemmondo E, Steinfeld R, Lavoy G, Kwarisiima D, Sang N, Jain V, Thirumurthy H, Liegler T, Balzer LB, Petersen ML, Cohen CR, Bukusi EA, Kamya MR, Havlir DV, Charlebois ED. A hybrid mobile approach for population-wide HIV testing in rural east Africa: an observational study. Lancet HIV. 2016 Mar;3(3):e111-9. doi: 10.1016/S2352-3018(15)00251-9. Epub 2016 Jan 26.</citation>
    <PMID>26939734</PMID>
  </results_reference>
  <results_reference>
    <citation>Katrak S, Day N, Ssemmondo E, Kwarisiima D, Midekisa A, Greenhouse B, Kamya M, Havlir D, Dorsey G. Community-wide Prevalence of Malaria Parasitemia in HIV-Infected and Uninfected Populations in a High-Transmission Setting in Uganda. J Infect Dis. 2016 Jun 15;213(12):1971-8. doi: 10.1093/infdis/jiw057. Epub 2016 Feb 10.</citation>
    <PMID>26908725</PMID>
  </results_reference>
  <results_reference>
    <citation>Kadede K, Ruel T, Kabami J, Ssemmondo E, Sang N, Kwarisiima D, Bukusi E, Cohen CR, Liegler T, Clark TD, Charlebois ED, Petersen ML, Kamya MR, Havlir DV, Chamie G; SEARCH team. Increased adolescent HIV testing with a hybrid mobile strategy in Uganda and Kenya. AIDS. 2016 Sep 10;30(14):2121-6. doi: 10.1097/QAD.0000000000001180.</citation>
    <PMID>27258399</PMID>
  </results_reference>
  <results_reference>
    <citation>Jain V, Chang W, Byonanebye DM, Owaraganise A, Twinomuhwezi E, Amanyire G, Black D, Marseille E, Kamya MR, Havlir DV, Kahn JG. Estimated Costs for Delivery of HIV Antiretroviral Therapy to Individuals with CD4+ T-Cell Counts &gt;350 cells/uL in Rural Uganda. PLoS One. 2015 Dec 3;10(12):e0143433. doi: 10.1371/journal.pone.0143433. eCollection 2015.</citation>
    <PMID>26632823</PMID>
  </results_reference>
  <results_reference>
    <citation>Balzer LB, Petersen ML, van der Laan MJ; SEARCH Collaboration. Targeted estimation and inference for the sample average treatment effect in trials with and without pair-matching. Stat Med. 2016 Sep 20;35(21):3717-32. doi: 10.1002/sim.6965. Epub 2016 Apr 18.</citation>
    <PMID>27087478</PMID>
  </results_reference>
  <results_reference>
    <citation>Thirumurthy H, Jakubowski A, Camlin C, Kabami J, Ssemmondo E, Elly A, Mwai D, Clark T, Cohen C, Bukusi E, Kamya M, Petersen M, Havlir D, Charlebois ED. Expectations about future health and longevity in Kenyan and Ugandan communities receiving a universal test-and-treat intervention in the SEARCH trial. AIDS Care. 2016;28 Suppl 3:90-8. doi: 10.1080/09540121.2016.1178959.</citation>
    <PMID>27421056</PMID>
  </results_reference>
  <results_reference>
    <citation>Maeri I, El Ayadi A, Getahun M, Charlebois E, Akatukwasa C, Tumwebaze D, Itiakorit H, Owino L, Kwarisiima D, Ssemmondo E, Sang N, Kabami J, Clark TD, Petersen M, Cohen CR, Bukusi EA, Kamya M, Havlir D, Camlin CS; SEARCH Collaboration. &quot;How can I tell?&quot; Consequences of HIV status disclosure among couples in eastern African communities in the context of an ongoing HIV &quot;test-and-treat&quot; trial. AIDS Care. 2016;28 Suppl 3:59-66. doi: 10.1080/09540121.2016.1168917.</citation>
    <PMID>27421052</PMID>
  </results_reference>
  <results_reference>
    <citation>Camlin CS, Ssemmondo E, Chamie G, El Ayadi AM, Kwarisiima D, Sang N, Kabami J, Charlebois E, Petersen M, Clark TD, Bukusi EA, Cohen CR, R Kamya M, Havlir D; SEARCH Collaboration. Men &quot;missing&quot; from population-based HIV testing: insights from qualitative research. AIDS Care. 2016;28 Suppl 3:67-73. doi: 10.1080/09540121.2016.1164806.</citation>
    <PMID>27421053</PMID>
  </results_reference>
  <results_reference>
    <citation>Jain V, Petersen ML, Liegler T, Byonanebye DM, Kwarisiima D, Chamie G, Sang N, Black D, Clark TD, Ladai A, Plenty A, Kabami J, Ssemmondo E, Bukusi EA, Cohen CR, Charlebois ED, Kamya MR, Havlir DV; SEARCH Collaboration. Population levels and geographical distribution of HIV RNA in rural Ugandan and Kenyan communities, including serodiscordant couples: a cross-sectional analysis. Lancet HIV. 2017 Mar;4(3):e122-e133. doi: 10.1016/S2352-3018(16)30220-X. Epub 2016 Dec 16. Erratum in: Lancet HIV. 2017 Mar;4(3):e102.</citation>
    <PMID>27989576</PMID>
  </results_reference>
  <results_reference>
    <citation>Brown LB, Havlir DV, Ayieko J, Mwangwa F, Owaraganise A, Kwarisiima D, Jain V, Ruel T, Clark T, Chamie G, Bukusi EA, Cohen CR, Kamya MR, Petersen ML, Charlebois ED; SEARCH Collaboration. High levels of retention in care with streamlined care and universal test and treat in East Africa. AIDS. 2016 Nov 28;30(18):2855-2864.</citation>
    <PMID>27603290</PMID>
  </results_reference>
  <results_reference>
    <citation>Chang W, Chamie G, Mwai D, Clark TD, Thirumurthy H, Charlebois ED, Petersen M, Kabami J, Ssemmondo E, Kadede K, Kwarisiima D, Sang N, Bukusi EA, Cohen CR, Kamya M, Havlir DV, Kahn JG. Implementation and Operational Research: Cost and Efficiency of a Hybrid Mobile Multidisease Testing Approach With High HIV Testing Coverage in East Africa. J Acquir Immune Defic Syndr. 2016 Nov 1;73(3):e39-e45.</citation>
    <PMID>27741031</PMID>
  </results_reference>
  <results_reference>
    <citation>Brown LB, Ayieko J, Mwangwa F, Owaraganise A, Kwarisiima D, Jain V, Ruel T, Clark T, Black D, Chamie G, Bukusi EA, Cohen CR, Kamya MR, Petersen ML, Charlebois ED, Havlir DV. Predictors of Retention in HIV Care Among Youth (15-24) in a Universal Test-and-Treat Setting in Rural Kenya. J Acquir Immune Defic Syndr. 2017 Sep 1;76(1):e15-e18. doi: 10.1097/QAI.0000000000001390.</citation>
    <PMID>28394821</PMID>
  </results_reference>
  <results_reference>
    <citation>Ssemmondo E, Mwangwa F, Kironde JL, Kwarisiima D, Clark TD, Marquez C, Charlebois ED, Petersen ML, Kamya MR, Havlir DV, Chamie G; SEARCH Collaboration. Implementation and Operational Research: Population-Based Active Tuberculosis Case Finding During Large-Scale Mobile HIV Testing Campaigns in Rural Uganda. J Acquir Immune Defic Syndr. 2016 Nov 1;73(3):e46-e50.</citation>
    <PMID>27741032</PMID>
  </results_reference>
  <results_reference>
    <citation>Petersen M, Balzer L, Kwarsiima D, Sang N, Chamie G, Ayieko J, Kabami J, Owaraganise A, Liegler T, Mwangwa F, Kadede K, Jain V, Plenty A, Brown L, Lavoy G, Schwab J, Black D, van der Laan M, Bukusi EA, Cohen CR, Clark TD, Charlebois E, Kamya M, Havlir D. Association of Implementation of a Universal Testing and Treatment Intervention With HIV Diagnosis, Receipt of Antiretroviral Therapy, and Viral Suppression in East Africa. JAMA. 2017 Jun 6;317(21):2196-2206. doi: 10.1001/jama.2017.5705.</citation>
    <PMID>28586888</PMID>
  </results_reference>
  <results_reference>
    <citation>Zheng W, Balzer L, van der Laan M, Petersen M; SEARCH Collaboration. Constrained binary classification using ensemble learning: an application to cost-efficient targeted PrEP strategies. Stat Med. 2018 Jan 30;37(2):261-279. doi: 10.1002/sim.7296. Epub 2017 Apr 6.</citation>
    <PMID>28384841</PMID>
  </results_reference>
  <results_reference>
    <citation>Mwangwa F, Chamie G, Kwarisiima D, Ayieko J, Owaraganise A, Ruel TD, Plenty A, Tram KH, Clark TD, Cohen CR, Bukusi EA, Petersen M, Kamya MR, Charlebois ED, Havlir DV, Marquez C. Gaps in the Child Tuberculosis Care Cascade in 32 Rural Communities in Uganda and Kenya. J Clin Tuberc Other Mycobact Dis. 2017 Dec;9:24-29. doi: 10.1016/j.jctube.2017.10.003.</citation>
    <PMID>29291251</PMID>
  </results_reference>
  <results_reference>
    <citation>Camlin CS, Charlebois ED, Geng E, Semitala F, Wallenta J, Getahun M, Kampiire L, Bukusi EA, Sang N, Kwarisiima D, Clark TD, Petersen ML, Kamya MR, Havlir DV. Redemption of the &quot;spoiled identity:&quot; the role of HIV-positive individuals in HIV care cascade interventions. J Int AIDS Soc. 2017 Dec;20(4). doi: 10.1002/jia2.25023.</citation>
    <PMID>29210185</PMID>
  </results_reference>
  <results_reference>
    <citation>Koss CA, Ayieko J, Mwangwa F, Owaraganise A, Kwarisiima D, Balzer LB, Plenty A, Sang N, Kabami J, Ruel TD, Black D, Camlin CS, Cohen CR, Bukusi EA, Clark TD, Charlebois ED, Petersen ML, Kamya MR, Havlir DV; SEARCH Collaboration. Early Adopters of Human Immunodeficiency Virus Preexposure Prophylaxis in a Population-based Combination Prevention Study in Rural Kenya and Uganda. Clin Infect Dis. 2018 Nov 28;67(12):1853-1860. doi: 10.1093/cid/ciy390.</citation>
    <PMID>29741594</PMID>
  </results_reference>
  <results_reference>
    <citation>Camlin CS, Koss CA, Getahun M, Owino L, Itiakorit H, Akatukwasa C, Maeri I, Bakanoma R, Onyango A, Atwine F, Ayieko J, Kabami J, Mwangwa F, Atukunda M, Owaraganise A, Kwarisiima D, Sang N, Bukusi EA, Kamya MR, Petersen ML, Cohen CR, Charlebois ED, Havlir DV. Understanding Demand for PrEP and Early Experiences of PrEP Use Among Young Adults in Rural Kenya and Uganda: A Qualitative Study. AIDS Behav. 2020 Jul;24(7):2149-2162. doi: 10.1007/s10461-020-02780-x.</citation>
    <PMID>31955361</PMID>
  </results_reference>
  <results_reference>
    <citation>Heller DJ, Balzer LB, Kazi D, Charlebois ED, Kwarisiima D, Mwangwa F, Jain V, Kotwani P, Chamie G, Cohen CR, Clark TD, Ayieko J, Byonanabye DM, Petersen M, Kamya MR, Havlir D, Kahn JG. Hypertension testing and treatment in Uganda and Kenya through the SEARCH study: An implementation fidelity and outcome evaluation. PLoS One. 2020 Jan 15;15(1):e0222801. doi: 10.1371/journal.pone.0222801. eCollection 2020.</citation>
    <PMID>31940346</PMID>
  </results_reference>
  <results_reference>
    <citation>Brown LB, Balzer LB, Kabami J, Kwarisiima D, Sang N, Ayieko J, Chen Y, Chamie G, Charlebois ED, Camlin CS, Cohen CR, Bukusi E, Kamya MR, Moody J, Havlir DV, Petersen ML. The Influence of Social Networks on Antiretroviral Therapy Initiation Among HIV-Infected Antiretroviral Therapy-Naive Youth in Rural Kenya and Uganda. J Acquir Immune Defic Syndr. 2020 Jan 1;83(1):9-15. doi: 10.1097/QAI.0000000000002199.</citation>
    <PMID>31809357</PMID>
  </results_reference>
  <results_reference>
    <citation>Olilo WA, Petersen ML, Koss CA, Wafula E, Kwarisiima D, Kadede K, Clark TD, Cohen CR, Bukusi EA, Kamya MR, Charlebois ED, Havlir DV, Ayieko J; SEARCH Collaboration. Pre-exposure Prophylaxis (PrEP) Uptake Among Older Individuals in Rural Western Kenya. J Acquir Immune Defic Syndr. 2019 Dec 1;82(4):e50-e53. doi: 10.1097/QAI.0000000000002150.</citation>
    <PMID>31490343</PMID>
  </results_reference>
  <results_reference>
    <citation>Chamie G, Kamya MR, Petersen ML, Havlir DV. Reaching 90-90-90 in rural communities in East Africa: lessons from the Sustainable East Africa Research in Community Health Trial. Curr Opin HIV AIDS. 2019 Nov;14(6):449-454. doi: 10.1097/COH.0000000000000585. Review.</citation>
    <PMID>31589172</PMID>
  </results_reference>
  <results_reference>
    <citation>Havlir DV, Balzer LB, Charlebois ED, Clark TD, Kwarisiima D, Ayieko J, Kabami J, Sang N, Liegler T, Chamie G, Camlin CS, Jain V, Kadede K, Atukunda M, Ruel T, Shade SB, Ssemmondo E, Byonanebye DM, Mwangwa F, Owaraganise A, Olilo W, Black D, Snyman K, Burger R, Getahun M, Achando J, Awuonda B, Nakato H, Kironde J, Okiror S, Thirumurthy H, Koss C, Brown L, Marquez C, Schwab J, Lavoy G, Plenty A, Mugoma Wafula E, Omanya P, Chen YH, Rooney JF, Bacon M, van der Laan M, Cohen CR, Bukusi E, Kamya MR, Petersen M. HIV Testing and Treatment with the Use of a Community Health Approach in Rural Africa. N Engl J Med. 2019 Jul 18;381(3):219-229. doi: 10.1056/NEJMoa1809866.</citation>
    <PMID>31314966</PMID>
  </results_reference>
  <results_reference>
    <citation>Tram KH, Mwangwa F, Chamie G, Atukunda M, Owaraganise A, Ayieko J, Jain V, Clark TD, Kwarisiima D, Petersen ML, Kamya MR, Charlebois ED, Havlir DV, Marquez C; SEARCH collaboration. Predictors of isoniazid preventive therapy completion among HIV-infected patients receiving differentiated and non-differentiated HIV care in rural Uganda. AIDS Care. 2020 Jan;32(1):119-127. doi: 10.1080/09540121.2019.1619661. Epub 2019 Jun 10.</citation>
    <PMID>31181961</PMID>
  </results_reference>
  <results_reference>
    <citation>Kwarisiima D, Atukunda M, Owaraganise A, Chamie G, Clark T, Kabami J, Jain V, Byonanebye D, Mwangwa F, Balzer LB, Charlebois E, Kamya MR, Petersen M, Havlir DV, Brown LB. Hypertension control in integrated HIV and chronic disease clinics in Uganda in the SEARCH study. BMC Public Health. 2019 May 6;19(1):511. doi: 10.1186/s12889-019-6838-6.</citation>
    <PMID>31060545</PMID>
  </results_reference>
  <results_reference>
    <citation>Mayer CM, Owaraganise A, Kabami J, Kwarisiima D, Koss CA, Charlebois ED, Kamya MR, Petersen ML, Havlir DV, Jewell BL. Distance to clinic is a barrier to PrEP uptake and visit attendance in a community in rural Uganda. J Int AIDS Soc. 2019 Apr;22(4):e25276. doi: 10.1002/jia2.25276.</citation>
    <PMID>31037845</PMID>
  </results_reference>
  <results_reference>
    <citation>Camlin CS, Akullian A, Neilands TB, Getahun M, Bershteyn A, Ssali S, Geng E, Gandhi M, Cohen CR, Maeri I, Eyul P, Petersen ML, Havlir DV, Kamya MR, Bukusi EA, Charlebois ED. Gendered dimensions of population mobility associated with HIV across three epidemics in rural Eastern Africa. Health Place. 2019 May;57:339-351. doi: 10.1016/j.healthplace.2019.05.002. Epub 2019 May 29.</citation>
    <PMID>31152972</PMID>
  </results_reference>
  <results_reference>
    <citation>Ayieko J, Petersen ML, Charlebois ED, Brown LB, Clark TD, Kwarisiima D, Kamya MR, Cohen CR, Bukusi EA, Havlir DV, Van Rie A. A Patient-Centered Multicomponent Strategy for Accelerated Linkage to Care Following Community-Wide HIV Testing in Rural Uganda and Kenya. J Acquir Immune Defic Syndr. 2019 Apr 1;80(4):414-422. doi: 10.1097/QAI.0000000000001939.</citation>
    <PMID>30807481</PMID>
  </results_reference>
  <results_reference>
    <citation>Brown LB, Getahun M, Ayieko J, Kwarisiima D, Owaraganise A, Atukunda M, Olilo W, Clark T, Bukusi EA, Cohen CR, Kamya MR, Petersen ML, Charlebois ED, Havlir DV, Camlin CS. Factors predictive of successful retention in care among HIV-infected men in a universal test-and-treat setting in Uganda and Kenya: A mixed methods analysis. PLoS One. 2019 Jan 23;14(1):e0210126. doi: 10.1371/journal.pone.0210126. eCollection 2019.</citation>
    <PMID>30673744</PMID>
  </results_reference>
  <results_reference>
    <citation>Shade SB, Osmand T, Luo A, Aine R, Assurah E, Mwebaza B, Mwai D, Owaraganise A, Mwangwa F, Ayieko J, Black D, Brown LB, Clark TD, Kwarisiima D, Thirumurthy H, Cohen CR, Bukusi EA, Charlebois ED, Balzer L, Kamya MR, Petersen ML, Havlir DV, Jain V. Costs of streamlined HIV care delivery in rural Ugandan and Kenyan clinics in the SEARCH Studys. AIDS. 2018 Sep 24;32(15):2179-2188. doi: 10.1097/QAD.0000000000001958.</citation>
    <PMID>30134294</PMID>
  </results_reference>
  <results_reference>
    <citation>Marquez C, Atukunda M, Balzer LB, Chamie G, Kironde J, Ssemmondo E, Ruel TD, Mwangwa F, Tram KH, Clark TD, Kwarisiima D, Petersen M, Kamya MR, Charlebois ED, Havlir DV. The age-specific burden and household and school-based predictors of child and adolescent tuberculosis infection in rural Uganda. PLoS One. 2020 Jan 29;15(1):e0228102. doi: 10.1371/journal.pone.0228102. eCollection 2020.</citation>
    <PMID>31995631</PMID>
  </results_reference>
  <results_reference>
    <citation>Havlir D, Lockman S, Ayles H, Larmarange J, Chamie G, Gaolathe T, Iwuji C, Fidler S, Kamya M, Floyd S, Moore J, Hayes R, Petersen M, Dabis F; (Universal Test, Treat Trials) UT3 Consortium. What do the Universal Test and Treat trials tell us about the path to HIV epidemic control? J Int AIDS Soc. 2020 Feb;23(2):e25455. doi: 10.1002/jia2.25455.</citation>
    <PMID>32091179</PMID>
  </results_reference>
  <results_reference>
    <citation>Muiru AN, Charlebois ED, Balzer LB, Kwarisiima D, Elly A, Black D, Okiror S, Kabami J, Atukunda M, Snyman K, Petersen M, Kamya M, Havlir D, Estrella MM, Hsu CY. The epidemiology of chronic kidney disease (CKD) in rural East Africa: A population-based study. PLoS One. 2020 Mar 4;15(3):e0229649. doi: 10.1371/journal.pone.0229649. eCollection 2020.</citation>
    <PMID>32130245</PMID>
  </results_reference>
  <results_reference>
    <citation>Koss CA, Charlebois ED, Ayieko J, Kwarisiima D, Kabami J, Balzer LB, Atukunda M, Mwangwa F, Peng J, Mwinike Y, Owaraganise A, Chamie G, Jain V, Sang N, Olilo W, Brown LB, Marquez C, Zhang K, Ruel TD, Camlin CS, Rooney JF, Black D, Clark TD, Gandhi M, Cohen CR, Bukusi EA, Petersen ML, Kamya MR, Havlir DV; SEARCH Collaboration. Uptake, engagement, and adherence to pre-exposure prophylaxis offered after population HIV testing in rural Kenya and Uganda: 72-week interim analysis of observational data from the SEARCH study. Lancet HIV. 2020 Apr;7(4):e249-e261. doi: 10.1016/S2352-3018(19)30433-3. Epub 2020 Feb 19.</citation>
    <PMID>32087152</PMID>
  </results_reference>
  <results_reference>
    <citation>Chamie G, Hickey MD, Kwarisiima D, Ayieko J, Kamya MR, Havlir DV. Universal HIV Testing and Treatment (UTT) Integrated with Chronic Disease Screening and Treatment: the SEARCH study. Curr HIV/AIDS Rep. 2020 Aug;17(4):315-323. doi: 10.1007/s11904-020-00500-7. Review.</citation>
    <PMID>32507985</PMID>
  </results_reference>
  <results_reference>
    <citation>Kabami J, Balzer LB, Saddiki H, Ayieko J, Kwarisiima D, Atukunda M, Charlebois ED, Clark TD, Koss CA, Ruel T, Bukusi EA, Cohen CR, Musoke P, Petersen ML, Havlir DV, Kamya MR, Chamie G. Population-level viral suppression among pregnant and postpartum women in a universal test and treat trial. AIDS. 2020 Jul 15;34(9):1407-1415. doi: 10.1097/QAD.0000000000002564.</citation>
    <PMID>32472768</PMID>
  </results_reference>
  <results_reference>
    <citation>Hickey MD, Ayieko J, Kwarisiima D, Opel FJ, Owaraganise A, Balzer LB, Chamie G, Jain V, Peng J, Camlin C, Charlebois ED, Cohen CR, Bukusi EA, Kamya MR, Petersen ML, Havlir DV. Improved Viral Suppression With Streamlined Care in the SEARCH Study. J Acquir Immune Defic Syndr. 2020 Dec 15;85(5):571-578. doi: 10.1097/QAI.0000000000002508.</citation>
    <PMID>32991337</PMID>
  </results_reference>
  <results_reference>
    <citation>Camlin CS, Charlebois ED, Getahun M, Akatukwasa C, Atwine F, Itiakorit H, Bakanoma R, Maeri I, Owino L, Onyango A, Chamie G, Clark TD, Cohen CR, Kwarisiima D, Kabami J, Sang N, Kamya MR, Bukusi EA, Petersen ML, V Havlir D. Pathways for reduction of HIV-related stigma: a model derived from longitudinal qualitative research in Kenya and Uganda. J Int AIDS Soc. 2020 Dec;23(12):e25647. doi: 10.1002/jia2.25647.</citation>
    <PMID>33283986</PMID>
  </results_reference>
  <results_reference>
    <citation>Koss CA, Havlir DV, Ayieko J, Kwarisiima D, Kabami J, Chamie G, Atukunda M, Mwinike Y, Mwangwa F, Owaraganise A, Peng J, Olilo W, Snyman K, Awuonda B, Clark TD, Black D, Nugent J, Brown LB, Marquez C, Okochi H, Zhang K, Camlin CS, Jain V, Gandhi M, Cohen CR, Bukusi EA, Charlebois ED, Petersen ML, Kamya MR, Balzer LB. HIV incidence after pre-exposure prophylaxis initiation among women and men at elevated HIV risk: A population-based study in rural Kenya and Uganda. PLoS Med. 2021 Feb 9;18(2):e1003492. doi: 10.1371/journal.pmed.1003492. eCollection 2021 Feb.</citation>
    <PMID>33561143</PMID>
  </results_reference>
  <results_reference>
    <citation>Nyabuti MN, Petersen ML, Bukusi EA, Kamya MR, Mwangwa F, Kabami J, Sang N, Charlebois ED, Balzer LB, Schwab JD, Camlin CS, Black D, Clark TD, Chamie G, Havlir DV, Ayieko J. Characteristics of HIV seroconverters in the setting of universal test and treat: Results from the SEARCH trial in rural Uganda and Kenya. PLoS One. 2021 Feb 5;16(2):e0243167. doi: 10.1371/journal.pone.0243167. eCollection 2021.</citation>
    <PMID>33544717</PMID>
  </results_reference>
  <results_reference>
    <citation>Shade SB, Osmand T, Kwarisiima D, Brown LB, Luo A, Mwebaza B, Mwesigye AR, Kwizera E, Imukeka H, Mwanga F, Ayieko J, Owaraganise A, Bukusi EA, Cohen CR, Charlebois ED, Black D, Clark TD, Petersen ML, Kamya MR, Havlir DV, Jain V. Costs of integrating hypertension care into HIV care in rural East African clinics. AIDS. 2021 May 1;35(6):911-919. doi: 10.1097/QAD.0000000000002834.</citation>
    <PMID>33821821</PMID>
  </results_reference>
  <results_reference>
    <citation>Chamie G, Kwarisiima D, Ndyabakira A, Marson K, Camlin CS, Havlir DV, Kamya MR, Thirumurthy H. Financial incentives and deposit contracts to promote HIV retesting in Uganda: A randomized trial. PLoS Med. 2021 May 4;18(5):e1003630. doi: 10.1371/journal.pmed.1003630. eCollection 2021 May.</citation>
    <PMID>33945526</PMID>
  </results_reference>
  <verification_date>February 2022</verification_date>
  <study_first_submitted>April 26, 2013</study_first_submitted>
  <study_first_submitted_qc>May 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2013</study_first_posted>
  <results_first_submitted>June 29, 2021</results_first_submitted>
  <results_first_submitted_qc>February 7, 2022</results_first_submitted_qc>
  <results_first_posted type="Actual">March 2, 2022</results_first_posted>
  <last_update_submitted>February 7, 2022</last_update_submitted>
  <last_update_submitted_qc>February 7, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV treatment and prevention</keyword>
  <keyword>Tuberculosis</keyword>
  <keyword>Community health campaign</keyword>
  <keyword>PrEP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT01864603/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 27, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT01864603/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>32 communities were enrolled and randomized to the intervention and control (16 per arm in each stage). We enrolled 150,395 community residents aged 15+ years at study baseline in Stage 1. At the start of Stage 2, 184,091 community residents (including in-migrants) aged 15+ years were enrolled. The analytic population for each endpoint is detailed in the Outcomes section.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Intervention</title>
          <description>Intervention arm first stage: annual universal community-based HIV and multi-disease testing; ART for all HIV+; ART delivery using streamlined patient-centered care&#xD;
Intervention arm second stage: Baseline universal community-based HIV and multi-disease testing; ART eligibility for all HIV+; ART delivery using streamlined patient-centered care; targeted population-level PrEP</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Active Comparator arm first stage: Baseline universal community-based HIV and multi-disease testing; ART eligibility and delivery by country standard of care&#xD;
Active Comparator arm second stage</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Stage 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="79818">Describes # of participants who were residents and aged 15+yrs at baseline</participants>
                <participants group_id="P2" count="70577">Describes # of participants who were residents and aged 15+yrs at baseline</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="71028"/>
                <participants group_id="P2" count="62912"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8790"/>
                <participants group_id="P2" count="7665"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Stage 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="91533">Describes # of participants who were residents and aged 15+yrs at the start of Stage 2</participants>
                <participants group_id="P2" count="92558">Describes # of participants who were residents and aged 15+yrs at the start of Stage 2</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5477"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="86056"/>
                <participants group_id="P2" count="92558"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>DSMB design modification</title>
              <participants_list>
                <participants group_id="P1" count="86056"/>
                <participants group_id="P2" count="92558"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Persons who were residents and aged 15+ years at baseline.</population>
      <group_list>
        <group group_id="B1">
          <title>Intervention</title>
          <description>Intervention arm first stage: Annual universal community- based HIV and multi-disease testing; ART eligibility for all HIV+; ART delivery using streamlined patient-centered care</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Active Comparator arm first stage: Baseline universal community-based HIV and multi-disease testing; ART eligibility and delivery by country standard of care</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="79818"/>
            <count group_id="B2" value="70577"/>
            <count group_id="B3" value="150395"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>15-20 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="79818"/>
                    <count group_id="B2" value="70577"/>
                    <count group_id="B3" value="150395"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20053"/>
                    <measurement group_id="B2" value="16602"/>
                    <measurement group_id="B3" value="36655"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>21-49 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="79818"/>
                    <count group_id="B2" value="70577"/>
                    <count group_id="B3" value="150395"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44047"/>
                    <measurement group_id="B2" value="39975"/>
                    <measurement group_id="B3" value="84022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=50 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="79818"/>
                    <count group_id="B2" value="70577"/>
                    <count group_id="B3" value="150395"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15718"/>
                    <measurement group_id="B2" value="14000"/>
                    <measurement group_id="B3" value="29718"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="79818"/>
                    <count group_id="B2" value="70577"/>
                    <count group_id="B3" value="150395"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43770"/>
                    <measurement group_id="B2" value="38644"/>
                    <measurement group_id="B3" value="82414"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36048"/>
                    <measurement group_id="B2" value="31933"/>
                    <measurement group_id="B3" value="67981"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="79818"/>
                    <count group_id="B2" value="70577"/>
                    <count group_id="B3" value="150395"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="79818"/>
                    <measurement group_id="B2" value="70577"/>
                    <measurement group_id="B3" value="150395"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Marital Status</title>
          <population>Marital status not reported by all participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="79604"/>
                    <count group_id="B2" value="70436"/>
                    <count group_id="B3" value="150040"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Single</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23692"/>
                    <measurement group_id="B2" value="19392"/>
                    <measurement group_id="B3" value="43084"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Married</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46684"/>
                    <measurement group_id="B2" value="42502"/>
                    <measurement group_id="B3" value="89186"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Widowed, divorced or separated</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9228"/>
                    <measurement group_id="B2" value="8542"/>
                    <measurement group_id="B3" value="17770"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Marital status - polygamous marriage</title>
          <population>Polygamous marriage status was not reported by all participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="79595"/>
                    <count group_id="B2" value="70429"/>
                    <count group_id="B3" value="150024"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9575"/>
                    <measurement group_id="B2" value="9210"/>
                    <measurement group_id="B3" value="18785"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Education</title>
          <population>Education was not reported by all participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="79656"/>
                    <count group_id="B2" value="70404"/>
                    <count group_id="B3" value="150060"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Below primary school</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50912"/>
                    <measurement group_id="B2" value="45691"/>
                    <measurement group_id="B3" value="96603"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Completed primary school</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11478"/>
                    <measurement group_id="B2" value="10305"/>
                    <measurement group_id="B3" value="21783"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Any secondary school or higher</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17266"/>
                    <measurement group_id="B2" value="14408"/>
                    <measurement group_id="B3" value="31674"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Occupation</title>
          <description>A formal sector occupation was defined as a teacher, student, government worker, military worker, health worker, or factory worker. A high-risk informal sector occupation was defined as a fishmonger, fisher, bar owner, bar worker, transportation worker, or tourism worker. A low-risk informal sector occupation was defined as a farmer, shopkeeper, market vendor, hotel worker, homemaker, household worker, construction worker, or miner.</description>
          <population>Occupation not reported by all participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="79597"/>
                    <count group_id="B2" value="70434"/>
                    <count group_id="B3" value="150031"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Formal sector</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19753"/>
                    <measurement group_id="B2" value="15733"/>
                    <measurement group_id="B3" value="35486"/>
                  </measurement_list>
                </category>
                <category>
                  <title>High-risk informal sector</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3235"/>
                    <measurement group_id="B2" value="4944"/>
                    <measurement group_id="B3" value="8179"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Low-risk informal sector</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48753"/>
                    <measurement group_id="B2" value="42341"/>
                    <measurement group_id="B3" value="91094"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3595"/>
                    <measurement group_id="B2" value="3201"/>
                    <measurement group_id="B3" value="6796"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No job or disabled</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4261"/>
                    <measurement group_id="B2" value="4215"/>
                    <measurement group_id="B3" value="8476"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Household wealth index quintile</title>
          <description>Quintiles were based on a principle components analysis of the household wealth survey and were calculated at the level of the household.</description>
          <population>Household wealth survey data was not collected on all households.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="79619"/>
                    <count group_id="B2" value="70280"/>
                    <count group_id="B3" value="149899"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>First, indicating least wealth</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12078"/>
                    <measurement group_id="B2" value="11876"/>
                    <measurement group_id="B3" value="23954"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Second</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13474"/>
                    <measurement group_id="B2" value="12652"/>
                    <measurement group_id="B3" value="26126"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Third</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15448"/>
                    <measurement group_id="B2" value="14371"/>
                    <measurement group_id="B3" value="29819"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Fourth</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17384"/>
                    <measurement group_id="B2" value="15703"/>
                    <measurement group_id="B3" value="33087"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Fifth, indicating most wealth</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21235"/>
                    <measurement group_id="B2" value="15678"/>
                    <measurement group_id="B3" value="36913"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stable residents</title>
          <description>Stable residents were defined as residents who had spent at least 6 months of the previous year in the trial community.</description>
          <population>Two participants did not have data recorded to determine as stable resident.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="79816"/>
                    <count group_id="B2" value="70577"/>
                    <count group_id="B3" value="150393"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76111"/>
                    <measurement group_id="B2" value="67759"/>
                    <measurement group_id="B3" value="143870"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Residents living with HIV</title>
          <population>HIV status was not available for all participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="71605"/>
                    <count group_id="B2" value="63879"/>
                    <count group_id="B3" value="135484"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7212"/>
                    <measurement group_id="B2" value="6317"/>
                    <measurement group_id="B3" value="13529"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Residents with prevalent hypertension</title>
          <description>Previous or current self-report of prior diagnosis OR previous or current systolic blood pressure &gt; 140 mmHg or diastolic blood pressure &gt; 90 mmHg on all 3 measurements at the health campaign or on all measures if &lt; 3 measurements done</description>
          <population>Adults 30 years of age or older were included in the analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28877"/>
                    <count group_id="B2" value="26884"/>
                    <count group_id="B3" value="55761"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5953"/>
                    <measurement group_id="B2" value="5911"/>
                    <measurement group_id="B3" value="11864"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cumulative HIV Incidence</title>
        <description>Cumulative 3 year HIV incidence in men and women ages ≥15 years after the start of Phase I intervention.&#xD;
Mean was calculated as the average across clusters of the cluster-level cumulative incidence.</description>
        <time_frame>3 years follow up</time_frame>
        <population>Baseline HIV- stable adult (15+years) residents</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Annual universal community-based HIV and multi-disease testing; ART eligibility for all HIV+; ART delivery using streamlined patient-centered care</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Baseline community-based HIV and multi-disease testing; ART eligibility and delivery by country standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative HIV Incidence</title>
          <description>Cumulative 3 year HIV incidence in men and women ages ≥15 years after the start of Phase I intervention.&#xD;
Mean was calculated as the average across clusters of the cluster-level cumulative incidence.</description>
          <population>Baseline HIV- stable adult (15+years) residents</population>
          <units>cumulative events per 100 persons</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Communities</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61676"/>
                <count group_id="O2" value="55438"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Communities</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" lower_limit="0.60" upper_limit="0.93"/>
                    <measurement group_id="O2" value="0.81" lower_limit="0.68" upper_limit="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Phase 1 arms</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HIV Incidence</title>
        <description>HIV incidence rate in men and women ages ≥15 years after the start of Phase II intervention (started after 3 years of Phase I).</description>
        <time_frame>3 years follow up</time_frame>
        <population>Intervention population consists of persons aged 15+ years who initiated PrEP in Phase II intervention communities. The comparator population consists of propensity score matched historical controls from Phase I intervention communities. HIV testing was not comprehensively conducted during Phase 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Baseline universal community-based HIV and multi-disease testing; ART eligibility for all HIV+; ART delivery using streamlined patient-centered care; targeted population-level PrEP</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Baseline community-based HIV and multi-disease testing; ART eligibility and delivery by country standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>HIV Incidence</title>
          <description>HIV incidence rate in men and women ages ≥15 years after the start of Phase II intervention (started after 3 years of Phase I).</description>
          <population>Intervention population consists of persons aged 15+ years who initiated PrEP in Phase II intervention communities. The comparator population consists of propensity score matched historical controls from Phase I intervention communities. HIV testing was not comprehensively conducted during Phase 2.</population>
          <units>Incident HIV per 100 person-year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5477"/>
                <count group_id="O2" value="2061"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" lower_limit="0.22" upper_limit="0.49"/>
                    <measurement group_id="O2" value="0.92" lower_limit="0.49" upper_limit="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Rate ratio</param_type>
            <param_value>0.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.09</ci_lower_limit>
            <ci_upper_limit>0.75</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incident TB Associated With HIV</title>
        <description>Cumulative incidence of TB or death due to illness among HIV+ population. Mean was calculated as the average across clusters of the cluster-level cumulative incidence.</description>
        <time_frame>3 years follow up</time_frame>
        <population>Adults without active TB and with HIV at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Annual universal community-based HIV and multi-disease testing; ART eligibility for all HIV+; ART delivery using streamlined patient-centered care</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Baseline community-based HIV and multi-disease testing; ART eligibility and delivery by country standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>Incident TB Associated With HIV</title>
          <description>Cumulative incidence of TB or death due to illness among HIV+ population. Mean was calculated as the average across clusters of the cluster-level cumulative incidence.</description>
          <population>Adults without active TB and with HIV at baseline</population>
          <units>cumulative events per 100 persons</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Communities</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7022"/>
                <count group_id="O2" value="6148"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Communities</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" lower_limit="3.2" upper_limit="4.1"/>
                    <measurement group_id="O2" value="4.6" lower_limit="4.1" upper_limit="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Mortality</title>
        <description>Mortality risk among HIV+ population. Mean was calculated as the average across clusters of the cluster-level cumulative incidence.</description>
        <time_frame>3 years follow up</time_frame>
        <population>Known HIV+ at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Annual universal community-based HIV and multi-disease testing; ART eligibility for all HIV+; ART delivery using streamlined patient-centered care</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Baseline community-based HIV and multi-disease testing; ART eligibility and delivery by country standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Mortality</title>
          <description>Mortality risk among HIV+ population. Mean was calculated as the average across clusters of the cluster-level cumulative incidence.</description>
          <population>Known HIV+ at baseline</population>
          <units>cumulative events per 100 persons</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Communities</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6971"/>
                <count group_id="O2" value="6095"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Communities</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="2.6" upper_limit="3.4"/>
                    <measurement group_id="O2" value="3.9" lower_limit="3.4" upper_limit="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HIV-free Infant Survival</title>
        <description>Probability of an infant born to an HIV+ mother remaining alive and HIV uninfected.&#xD;
Mean was calculated as the average across clusters of the cluster-level cumulative incidence.</description>
        <time_frame>3 years follow up</time_frame>
        <population>Infants born in study period to women with HIV</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Annual universal community-based HIV and multi-disease testing; ART eligibility for all HIV+; ART delivery using streamlined patient-centered care</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Baseline community-based HIV and multi-disease testing; ART eligibility and delivery by country standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>HIV-free Infant Survival</title>
          <description>Probability of an infant born to an HIV+ mother remaining alive and HIV uninfected.&#xD;
Mean was calculated as the average across clusters of the cluster-level cumulative incidence.</description>
          <population>Infants born in study period to women with HIV</population>
          <units>cumulative events per 100 persons</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Communities</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="564"/>
                <count group_id="O2" value="528"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Communities</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.7" lower_limit="94.4" upper_limit="99.0"/>
                    <measurement group_id="O2" value="93.6" lower_limit="92.0" upper_limit="95.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of HIV+ Adults With HIV RNA &lt;=500 c/mL</title>
        <description>Percent of HIV+ adults with HIV RNA &lt;=500 c/mL. Mean was calculated as the average across clusters of the cluster-level cumulative incidence.</description>
        <time_frame>3 years follow up</time_frame>
        <population>HIV+ adults at year 3, including those out of care or without a prior HIV diagnosis</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Annual universal community-based HIV and multi-disease testing; ART eligibility for all HIV+; ART delivery using streamlined patient-centered care</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Baseline community-based HIV and multi-disease testing; ART eligibility and delivery by country standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of HIV+ Adults With HIV RNA &lt;=500 c/mL</title>
          <description>Percent of HIV+ adults with HIV RNA &lt;=500 c/mL. Mean was calculated as the average across clusters of the cluster-level cumulative incidence.</description>
          <population>HIV+ adults at year 3, including those out of care or without a prior HIV diagnosis</population>
          <units>cumulative events per 100 persons</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Communities</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8399"/>
                <count group_id="O2" value="7349"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Communities</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" lower_limit="77" upper_limit="81"/>
                    <measurement group_id="O2" value="68" lower_limit="66" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time in Care for HIV+ Adults With Baseline Viremia</title>
        <description>Percent of time spent actively engaged in HIV care among HIV+ adults with baseline viremia</description>
        <time_frame>3 years follow up</time_frame>
        <population>HIV+ adults linked to care with baseline HIV RNA &gt;=500 c/mL</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Annual universal community-based HIV and multi-disease testing; ART eligibility for all HIV+; ART delivery using streamlined patient-centered care</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Baseline community-based HIV and multi-disease testing; ART eligibility and delivery by country standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>Time in Care for HIV+ Adults With Baseline Viremia</title>
          <description>Percent of time spent actively engaged in HIV care among HIV+ adults with baseline viremia</description>
          <population>HIV+ adults linked to care with baseline HIV RNA &gt;=500 c/mL</population>
          <units>percentage of days</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="330"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" lower_limit="79" upper_limit="83"/>
                    <measurement group_id="O2" value="73" lower_limit="68" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Incidence of ART-initiation</title>
        <description>Proportion of baseline HIV+ ART-naive persons who initiate ART Mean was calculated as the average across clusters of the cluster-level cumulative incidence.</description>
        <time_frame>3 years follow up</time_frame>
        <population>Baseline HIV+ without previous or current ART</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Annual universal community-based HIV and multi-disease testing; ART eligibility for all HIV+; ART delivery using streamlined patient-centered care</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Baseline community-based HIV and multi-disease testing; ART eligibility and delivery by country standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Incidence of ART-initiation</title>
          <description>Proportion of baseline HIV+ ART-naive persons who initiate ART Mean was calculated as the average across clusters of the cluster-level cumulative incidence.</description>
          <population>Baseline HIV+ without previous or current ART</population>
          <units>cumulative events per 100 persons</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Communities</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3002"/>
                <count group_id="O2" value="2950"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Communities</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="80" upper_limit="85"/>
                    <measurement group_id="O2" value="50" lower_limit="46" upper_limit="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hypertension Control</title>
        <description>hypertension control (greater than or equal to 140 mg Hg systolic or 90 mg Hg diastolic after 3 repeated readings) at year 3 among adults aged &gt;= 30 years with hypertension.&#xD;
Mean was calculated as the average across clusters of the cluster-level cumulative incidence.</description>
        <time_frame>3 years follow up</time_frame>
        <population>Hypertensive adults (aged 30+) at year 3</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Annual universal community-based HIV and multi-disease testing; ART eligibility for all HIV+; ART delivery using streamlined patient-centered care</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Baseline community-based HIV and multi-disease testing; ART eligibility and delivery by country standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>Hypertension Control</title>
          <description>hypertension control (greater than or equal to 140 mg Hg systolic or 90 mg Hg diastolic after 3 repeated readings) at year 3 among adults aged &gt;= 30 years with hypertension.&#xD;
Mean was calculated as the average across clusters of the cluster-level cumulative incidence.</description>
          <population>Hypertensive adults (aged 30+) at year 3</population>
          <units>cumulative events per 100 persons</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Communities</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11664"/>
                <count group_id="O2" value="10935"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Communities</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47" lower_limit="45" upper_limit="49"/>
                    <measurement group_id="O2" value="37" lower_limit="35" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adherence to PrEP Treatment</title>
        <description>Number of patients with adherence to PrEP treatment (self reported adherence at &gt;=1 visit)</description>
        <time_frame>3 years follow up</time_frame>
        <population>Persons who initiated PrEP eligible for a follow-up visit. No data were collected for the second stage in the control arm due to DSMB approved design modification.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Baseline universal community-based HIV and multi-disease testing; ART eligibility for all HIV+; ART delivery using streamlined patient-centered care; targeted population-level PrEP</description>
          </group>
        </group_list>
        <measure>
          <title>Adherence to PrEP Treatment</title>
          <description>Number of patients with adherence to PrEP treatment (self reported adherence at &gt;=1 visit)</description>
          <population>Persons who initiated PrEP eligible for a follow-up visit. No data were collected for the second stage in the control arm due to DSMB approved design modification.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5398"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Adults' on- and Off-farm Employment</title>
        <description>HIV+ adults with on- and off-farm employment</description>
        <time_frame>3 years follow up</time_frame>
        <population>Subsample of baseline HIV+ working-age adults (18-65)</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Annual universal community-based HIV and multi-disease testing; ART eligibility for all HIV+; ART delivery using streamlined patient-centered care</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Baseline community-based HIV and multi-disease testing; ART eligibility and delivery by country standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>Average Adults' on- and Off-farm Employment</title>
          <description>HIV+ adults with on- and off-farm employment</description>
          <population>Subsample of baseline HIV+ working-age adults (18-65)</population>
          <units>cumulative events per 100 persons</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1425"/>
                <count group_id="O2" value="1443"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.5" lower_limit="83.1" upper_limit="88.0"/>
                    <measurement group_id="O2" value="82.4" lower_limit="80" upper_limit="84.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Year 3 Viremia Among ART-experienced Persons With Baseline Viremia</title>
        <description>Plasma HIV RNA &lt;400 cps/ml Mean was calculated as the average across clusters of the cluster-level cumulative incidence.</description>
        <time_frame>3 years follow up</time_frame>
        <population>HIV+ ART experienced adults linked to care with baseline HIV RNA &gt;=500 c/mL</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Annual universal community-based HIV and multi-disease testing; ART eligibility for all HIV+; ART delivery using streamlined patient-centered care</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Baseline community-based HIV and multi-disease testing; ART eligibility and delivery by country standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>Year 3 Viremia Among ART-experienced Persons With Baseline Viremia</title>
          <description>Plasma HIV RNA &lt;400 cps/ml Mean was calculated as the average across clusters of the cluster-level cumulative incidence.</description>
          <population>HIV+ ART experienced adults linked to care with baseline HIV RNA &gt;=500 c/mL</population>
          <units>cumulative events per 100 persons</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Communities</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="330"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Communities</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" lower_limit="59" upper_limit="74"/>
                    <measurement group_id="O2" value="47" lower_limit="36" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Linkage to Care</title>
        <description>Proportion of Persons Attending an HIV Clinic Visit by 30 Days After HIV Test Mean was calculated as the average across clusters of the cluster-level cumulative incidence.</description>
        <time_frame>30 days after HIV test</time_frame>
        <population>Persons testing HIV+ and not in care</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Patient-centered Phone call</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Standard of Care</description>
          </group>
        </group_list>
        <measure>
          <title>Linkage to Care</title>
          <description>Proportion of Persons Attending an HIV Clinic Visit by 30 Days After HIV Test Mean was calculated as the average across clusters of the cluster-level cumulative incidence.</description>
          <population>Persons testing HIV+ and not in care</population>
          <units>cumulative events per 100 persons</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Communities</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Communities</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" lower_limit="29" upper_limit="53"/>
                    <measurement group_id="O2" value="24" lower_limit="13" upper_limit="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HIV Incidence Rate</title>
        <description>HIV incidence rates during the first and third year of follow up; Results from the Control arm are not provided because annual HIV incidence was not measured in the control arm (annual HIV testing was only conducted in the intervention arm).</description>
        <time_frame>3 years follow up</time_frame>
        <population>HIV-negative adults in stage 1 intervention arm who had repeat HIV testing</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Year 1</title>
            <description>Third year of Stage 1 intervention</description>
          </group>
          <group group_id="O2">
            <title>Intervention Year 3</title>
            <description>First year of Stage 1 Intervention: Annual universal community-based HIV and multi-disease testing; ART eligibility for all HIV+; ART delivery using streamlined patient-centered care</description>
          </group>
        </group_list>
        <measure>
          <title>HIV Incidence Rate</title>
          <description>HIV incidence rates during the first and third year of follow up; Results from the Control arm are not provided because annual HIV incidence was not measured in the control arm (annual HIV testing was only conducted in the intervention arm).</description>
          <population>HIV-negative adults in stage 1 intervention arm who had repeat HIV testing</population>
          <units>per 100 person-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52474"/>
                <count group_id="O2" value="58145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" lower_limit="0.38" upper_limit="0.49"/>
                    <measurement group_id="O2" value="0.31" lower_limit="0.26" upper_limit="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prevalence of Transmitted HIV Drug-resistance Mutations</title>
        <description>HIV NNRTI drug-resistance mutations found at baseline</description>
        <time_frame>Baseline</time_frame>
        <population>ART naive HIV+ persons at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Baseline universal community-based HIV and multi-disease testing; ART eligibility for all HIV+; ART delivery using streamlined patient-centered care; targeted population-level PrEP</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Baseline community-based HIV and multi-disease testing; ART eligibility and delivery by country standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>Prevalence of Transmitted HIV Drug-resistance Mutations</title>
          <description>HIV NNRTI drug-resistance mutations found at baseline</description>
          <population>ART naive HIV+ persons at baseline</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prevalence of Chronic Kidney Disease (CKD)</title>
        <description>Percentage of participants with chronic kidney disease (CKD)</description>
        <time_frame>3 years follow up</time_frame>
        <population>participants (age &gt;=18) who had a home visit during follow up year 3</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Baseline universal community-based HIV and multi-disease testing; ART eligibility for all HIV+; ART delivery using streamlined patient-centered care; targeted population-level PrEP</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Baseline community-based HIV and multi-disease testing; ART eligibility and delivery by country standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>Prevalence of Chronic Kidney Disease (CKD)</title>
          <description>Percentage of participants with chronic kidney disease (CKD)</description>
          <population>participants (age &gt;=18) who had a home visit during follow up year 3</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2100"/>
                <count group_id="O2" value="1505"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="361"/>
                    <measurement group_id="O2" value="248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Costs of Programming (ART)</title>
        <description>Cost of ART streamlined care delivery amount HIV+ persons</description>
        <time_frame>Follow up year 3</time_frame>
        <population>Units are Intervention clinics using streamlined care; participants are HIV+ with at least one streamlined care visit</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Baseline universal community-based HIV and multi-disease testing; ART eligibility for all HIV+; ART delivery using streamlined patient-centered care; targeted population-level PrEP</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Baseline community-based HIV and multi-disease testing; ART eligibility and delivery by country standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>Total Costs of Programming (ART)</title>
          <description>Cost of ART streamlined care delivery amount HIV+ persons</description>
          <population>Units are Intervention clinics using streamlined care; participants are HIV+ with at least one streamlined care visit</population>
          <units>USD per person year</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Clinics</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7700"/>
                <count group_id="O2" value="7700"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Clinics</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="291" lower_limit="279" upper_limit="303"/>
                    <measurement group_id="O2" value="221" lower_limit="196" upper_limit="246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Phase I: 3 years Phase II: 3 years</time_frame>
      <desc>This was a community randomized community-based trial. In accordance with our approved data safety monitoring plan, adverse events were monitored and assessed in a different population of patients than all cause mortality. Adverse events were only monitored for participants who received any biomedical treatment or prevention intervention outside of current country standard of care.</desc>
      <group_list>
        <group group_id="E1">
          <title>Intervention Arm Stage 1</title>
          <description>Annual universal community-based HIV and multi-disease testing; ART eligibility for all HIV+; ART delivery using streamlined patient-centered care&#xD;
Adverse events monitored among persons initiating ART outside of National guidelines</description>
        </group>
        <group group_id="E2">
          <title>Intervention Arm Stage II</title>
          <description>Baseline universal community-based HIV and multi-disease testing; ART eligibility for all HIV+; ART delivery using streamlined patient-centered care; targeted population-level PrEP&#xD;
Adverse events monitored among persons initiating PrEP</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NIH DAIDS Nov 2014</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1217" subjects_at_risk="79818"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="1671"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="5447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="1671"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Hemoptysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Blood clot in brain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1671"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="DAIDS Vers Nov 2014">Abdominal Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Intoxication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="1671"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Temperature</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Genital Ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1671"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Seroconversion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1671"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Typhoid</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1671"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Unintentional Weight Loss</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1671"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Soft Tissue Injury</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1671"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1671"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuromuscular weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Head Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1671"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pre-term Labor</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1671"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Spontaneous Abortion</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1671"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Fetal Demise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Cesarean Infant Delivery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1671"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Pre-eclampsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1671"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Ruptured Ectopic Pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1671"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Stillbirth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1671"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Altered Mental Status</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated ALT</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Elevated AST</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Elevated Creatinine</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1671"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>UTI</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title vocab="DAIDS Vers Nov 2014">Uterine Fibroids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1671"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Uterine Prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1671"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Pulmonary Tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1671"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="5447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cutaneous Eruption</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>NIH DAIDS Nov 2014</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="1671"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="5447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="DAIDS Vers Nov 2014">Anemia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="1671"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Leucopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye Discharge</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="DAIDS Vers Nov 2014">Abdominal Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1671"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1671"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Unintentional Weight Loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1671"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Dizzinesss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1671"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1671"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Spontaneous Abortion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1671"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Stillbirth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1671"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="5447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title vocab="DAIDS Vers Nov 2014">Altered Mental Status</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated ALT</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Elevated AST</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Elevated Creatinine</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title>Elevated Bilirubin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1671"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Gynaecomastia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title vocab="DAIDS Vers Nov 2014">Uterine Bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1671"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1671"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5447"/>
              </event>
              <event>
                <sub_title vocab="DAIDS Vers Nov 2014">Pruritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1671"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5447"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>In the second stage, following re-randomization, there was a DSMB approved study modification due to policy changes in standard of care. As a result, outcomes were only assessed among participants in the intervention arm who were offered PrEP. No data were collected in the control arm.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Tamara Clark</name_or_title>
      <organization>University of California, San Francisco</organization>
      <phone>628-206-8790</phone>
      <email>Tamara.Clark@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

